|
Feb 1
|
Sanofi (SNY) Q4 2023 Earnings Call Transcript
|
|
Feb 1
|
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
|
|
Feb 1
|
Sanofi appoints Nestlé executive as new finance chief
|
|
Feb 1
|
Sanofi Taps Nestle’s Roger as CFO After Swing to Net Loss
|
|
Feb 1
|
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
|
|
Feb 1
|
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
|
|
Jan 31
|
Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?
|
|
Jan 31
|
UPDATE 1-Teva Pharm sees lower 2024 profit after large Q4 beat
|
|
Jan 31
|
Why Sanofi (SNY) Might Surprise This Earnings Season
|
|
Jan 28
|
12 Best Foreign Dividend Stocks To Invest In
|
|
Jan 26
|
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
|
|
Jan 26
|
Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited
|
|
Jan 25
|
UPDATE 3-US FDA approves Dupixent to treat younger kids with esophageal condition
|
|
Jan 25
|
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
|
|
Jan 25
|
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
|
|
Jan 25
|
Why Wall Street no longer fears sprawling impact from the weight loss drug craze
|
|
Jan 25
|
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
|
|
Jan 24
|
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
|
|
Jan 24
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 24
|
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
|